Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Mink Intersects 7.1 Meters of 0.44% Ni, 0.28% Cu, 0.06% Co in Massive Sulphide at Warren Property (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Avalo Therapeutics Inc AVTX

Healthcare Biotechnology
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its... see more

Recent & Breaking News (NDAQ:AVTX)

Avalo Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire February 24, 2026

Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire February 18, 2026

Avalo Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire February 4, 2026

Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 17, 2025

Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates

GlobeNewswire November 6, 2025

Avalo Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire November 3, 2025

Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa

GlobeNewswire October 29, 2025

Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources

GlobeNewswire October 1, 2025

Avalo Therapeutics Appoints Kevin R. Lind to Board of Directors

GlobeNewswire September 22, 2025

Avalo Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire August 27, 2025

Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates

GlobeNewswire August 7, 2025

Avalo Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire June 23, 2025

Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors

GlobeNewswire June 18, 2025

Avalo Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire May 27, 2025

Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates

GlobeNewswire May 12, 2025

Avalo Therapeutics to Participate in The Citizens Life Sciences Conference

GlobeNewswire April 30, 2025

Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

GlobeNewswire March 26, 2025

Avalo Reports 2024 Financial Results and Recent Business Updates

GlobeNewswire March 20, 2025

Avalo Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire February 24, 2025

Avalo Therapeutics to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

GlobeNewswire February 4, 2025

Podcasts